Vanutide cridificar

Drug Profile

Vanutide cridificar

Alternative Names: AAC 001; ACC-001; Active beta-amyloid immunotherapeutic conjugate; Aβ immunotherapeutic conjugate; CRM 197; Peptide-CRM Conjugate; PF-05236806; PF-5236806

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Corporation; Wyeth
  • Developer JANSSEN Alzheimer Immunotherapy; Pfizer
  • Class Alzheimer vaccines; Antidementias; Carrier proteins; Immunoconjugates; Peptide fragments
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2016 Pfizer terminates a phase II long-term extension trial in Alzheimer's disease in USA (NCT00960531)
  • 01 Feb 2014 Pfizer and JANSSEN Alzheimer Immunotherapy complete a phase II trial in Alzheimer's disease in USA (NCT01227564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top